These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 28673279)

  • 1. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
    CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
    Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole Lauroxil: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
    Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
    Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
    Farwick S; Hickey MB; Jacobs G; Faldu SP; Vandiver J; Weiden PJ
    J Psychiatr Pract; 2019 Mar; 25(2):82-90. PubMed ID: 30849056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
    Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
    Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
    J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
    Shymko G; Dobson L; Acacio MC; Grace T; Tadier S; Waters F
    Schizophr Res; 2023 Jan; 251():74-81. PubMed ID: 36587541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.